Related Experiment Video
Updated: Jul 11, 2026
11:56
Derivation of Human Embryonic Stem Cells by Immunosurgery
Published on: December 13, 2007
Immunogenicity of human embryonic stem cells.
Karl-Henrik Grinnemo1, Christer Sylvén, Outi Hovatta
1Division of Cardiothoracic Surgery and Anaesthesiology, Department of Molecular Medicine and Surgery, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. karl-henrik.grinnemo@karolinska.se
Cell and Tissue Research
|September 12, 2007
Summary
Human embryonic stem cells (HESC) hold promise for regenerative medicine but face challenges like immune rejection. Strategies such as stem cell banking and tolerance induction are being explored for clinical applications.
Area of Science:
- Stem Cell Biology
- Immunology
- Regenerative Medicine
Background:
- Human embryonic stem cells (HESC) are pluripotent cells derived from blastocysts.
- HESC offer potential for treating degenerative diseases and replacing organ transplants.
- Clinical application of HESC is hindered by immune rejection, teratoma risk, and undefined culturing conditions.
Purpose of the Study:
- To review the immunological properties of HESC.
- To discuss strategies for overcoming immune rejection in HESC therapy.
- To explore potential solutions for the clinical use of HESC.
Main Methods:
- Review of existing literature on HESC immunology.
- Analysis of proposed methods for immune tolerance induction.
- Discussion of stem cell banking and somatic cell nuclear transfer.
Main Results:
- HESC possess unique immunological characteristics that can lead to rejection.
- Several strategies show promise in mitigating HESC immunogenicity.
- Techniques like co-stimulation blockade and mixed chimerism are investigated for tolerance induction.
Conclusions:
- Overcoming immune rejection is critical for the clinical translation of HESC therapies.
- A combination of strategies may be necessary to ensure successful HESC transplantation.
- Further research into HESC immunology and tolerance induction is essential for regenerative medicine.
Related Concept Videos
00:57Embryonic Stem Cells
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
00:58Embryonic Stem Cells
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
01:06Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...